Recruiting
Phase 2

PP405

Sponsor:

Pelage Pharmaceuticals, Inc.

Code:

NCT07907783

Conditions

Androgenetic Alopecia

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

PP405 0.05% Topical Gel

Vehicle Topical Gel

Study Details

Brief summary:

The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia

Conditions

Androgenetic Alopecia

Study ID

NCT07907783

Start date

Nov 10, 2026

Status verified date

Nov, 2026

Completion date

Mar, 2028

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Female (assigned at birth) aged 18 to 65 years, inclusive at time of consent.
2. Able and willing to provide written informed consent
3. Must have been experiencing Androgenetic Alopecia (AGA) for at least 6 months prior to screening.
4. Have a Savin Scale stages I-3, I-4, II-1, or II-2
5. Agree to comply with protocol procedures

Exclusion Criteria:

1. Concomitant diagnosis of non-AGA forms of alopecia.
2. Use of other hair loss treatments within periods specified in protocol.
3. Use of excluded medications as specified in protocol.
4. Diagnosis of other medical conditions as specified in protocol.
5. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: PP405 0.05% Topical Gel

PP405 applied to the scalp from Day 1 to Week 24

placebo comparator: Vehicle Topical Gel

Vehicle applied to the scalp from Day 1 to Week 24

Interventions

PP405 0.05% Topical Gel

Medicated topical gel containing PP405 0.05%

Vehicle Topical Gel

Topical gel

Primary outcome measure

  • Change from baseline in non-vellus target area hair count [ Time Frame: Week 24 ]

Central Contacts and Locations

Central contacts

Lisa Sherman, VP of Clinical Operations

(213) 218-3830clinicaltrials@pelagepharma.com

Locations

Burke Pharmaceutical Research

Recruiting

Hot Springs, Arkansas, United States, 71913

DelRicht Research (Experience Dermatology)

Recruiting

Atlanta, Georgia, United States, 30329

Equity Medical, LLC

Recruiting

New York, New York, United States, 10023

DelRicht @Mt Pleasant Dermatology

Recruiting

Mt. Pleasant, South Carolina, United States, 29464

DelRicht Research @Harpeth Valley Dermatology

Recruiting

Smyrna, Tennessee, United States, 37167

Institution: Delricht Research @Lockhart

Recruiting

Prosper, Texas, United States, 75078

More Information

Sponsor

Pelage Pharmaceuticals, Inc.

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Pelage Pharmaceuticals, Inc. on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.